Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05745298
Other study ID # 20221081
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 21, 2023
Est. completion date July 21, 2025

Study information

Verified date July 2023
Source University of Miami
Contact Gary J Farkas, PhD
Phone 305-243-4518
Email gjf50@med.miami.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this study is to improve unaided cough with abdominal and latissimus dorsi functional electrical stimulation in conjunction with respiratory muscle training in individuals with acute spinal cord injuries.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 21, 2025
Est. primary completion date July 21, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Traumatic and atraumatic C2- T12 Spinal cord injury (AIS A, B, and C motor incomplete and complete injuries) currently admitted to inpatient rehabilitation with an injury date < 12 months prior to enrollment 2. Positive response to electrical stimulation through a palpable contraction 3. Fluent in written and spoken English Exclusion Criteria: 1. Individuals who do not meet inclusion criteria 2. Prisoners 3. Concurrent traumatic brain injury determined by Rancho level of cognitive functioning < VI 4. Individuals with open tracheostomy 5. Persons with pacemakers 6. Pregnant women 7. Persons with epilepsy 8. Open wounds or metal implants at site of electrode placement 9. Unresponsive to functional electrical stimulation 10. Current diagnosis or history of thoraco-abdomino-pelvic cancer

Study Design


Intervention

Device:
Xcite Clinical Station
The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.

Locations

Country Name City State
United States University of Miami Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage change in peak cough flow (PCF) Assessing the percentage change in peak cough flow as assessed by peak expiratory flow meter with a pillow face mask. one week pre-intervention and up to 4 weeks post-intervention
Primary Percentage change in peak expiratory flow Assessing the percentage change in peak expiratory flow as assessed by peak expiratory flow meter with a pillow face mask. one week pre-intervention and up to 4 weeks post-intervention
Secondary Percentage change in forced expiratory volume in 1 second (FEV1) Assessing the percentage change in forced expiratory volume in 1 second (FEV1) as measured by the spirobank II. Measured in Liters/minute. one week pre-intervention and up to 4 weeks post-intervention
Secondary Percentage change in forced vital capacity (FVC) Assessing the percentage change in forced vital capacity (FVC) as measured by the spirobank II. Measured in Liters/minute. one week pre-intervention and up to 4 weeks post-intervention
Secondary Percentage change in maximum inspiratory pressure (MIP) Assessing the percentage change in maximum inspiratory pressure (MIP) as measured by the MicroSpiro. Measured in Liters/minute. one week pre-intervention and up to 4 weeks post-intervention
Secondary Percentage change in maximum expiratory pressure (MEP) Assessing the percentage change in maximum expiratory pressure (MEP) as measured by the MicroSpiro. Measured in Liters/minute. one week pre-intervention and up to 4 weeks post-intervention
Secondary Change in cough effectiveness as measured by Likert Scale The 5-point Likert scale will be used to obtain a self-rated perception of cough effectiveness. The participant will be asked to rate how strong and how well secretions were cleared after coughing. The rating scale will range from 1=very poor; 2=poor; 3=fair, 4=good; 5= very good. A score of 4 or 5 is classified as effectively clearing secretions after coughing. one week pre-intervention and up to 4 weeks post-intervention
See also
  Status Clinical Trial Phase
Recruiting NCT04811235 - Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial N/A
Completed NCT00406016 - Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI Phase 1
Recruiting NCT05305118 - TSCS for Acute SCI N/A
Recruiting NCT05244408 - "SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation
Recruiting NCT05731986 - Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI) N/A
Recruiting NCT06452264 - Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study N/A
Recruiting NCT05426681 - Spinal Cord Injury Neuroprotection With Glyburide Phase 1
Recruiting NCT04056988 - tSCI Contrast Enhanced Ultrasound Study Phase 4
Terminated NCT01750684 - AC105 in Patients With Acute Traumatic Spinal Cord Injury Phase 2
Recruiting NCT04475224 - Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury Phase 3
Enrolling by invitation NCT06030531 - Spasticity and Functional Recovery After SCI
Active, not recruiting NCT03935724 - Stem Cells in Spinal Cord Injury Phase 2/Phase 3
Recruiting NCT04054414 - PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury Phase 2
Recruiting NCT06000592 - Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI N/A
Completed NCT02325414 - Prevention of Bone Loss After Acute SCI by Zoledronic Acid Phase 2
Recruiting NCT02034669 - Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment Phase 1/Phase 2
Terminated NCT02232165 - Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury N/A
Completed NCT02260713 - Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study. Phase 1/Phase 2
Terminated NCT02524379 - Spinal Cord Injury Neuroprotection With Glyburide Phase 1/Phase 2
Completed NCT01502631 - Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI) Phase 2